Copyright
©The Author(s) 2023.
World J Clin Cases. Nov 6, 2023; 11(31): 7593-7609
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7593
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7593
Table 3 Analysis of topological parameters of key targets
Name | Closeness | Betweenness | Degree |
TP53 | 0.839506 | 0.095155 | 56 |
EGFR | 0.790698 | 0.051782 | 51 |
ALB | 0.781609 | 0.077526 | 50 |
ESR1 | 0.747253 | 0.054759 | 47 |
HSP90AA1 | 0.764045 | 0.074274 | 47 |
SRC | 0.73913 | 0.035499 | 45 |
HIF1A | 0.731183 | 0.023561 | 44 |
MAPK3 | 0.723404 | 0.033332 | 43 |
TNF | 0.708333 | 0.027768 | 41 |
MAPK1 | 0.660194 | 0.018393 | 34 |
PTGS2 | 0.660194 | 0.013252 | 34 |
SMAD3 | 0.635514 | 0.007272 | 30 |
AR | 0.618182 | 0.005023 | 29 |
STAT1 | 0.623853 | 0.00514 | 29 |
MMP9 | 0.62963 | 0.006427 | 29 |
IGF1R | 0.623853 | 0.00413 | 28 |
- Citation: Yang Q, Li LY. Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer. World J Clin Cases 2023; 11(31): 7593-7609
- URL: https://www.wjgnet.com/2307-8960/full/v11/i31/7593.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i31.7593